Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208761
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mesía Nin, Ricard | - |
dc.contributor.author | Rubió-Casadevall, Jordi | - |
dc.contributor.author | Cirauqui Cirauqui, Beatriz | - |
dc.contributor.author | Martinez Trufero, Javier | - |
dc.contributor.author | Plana Serrahima, Maria | - |
dc.contributor.author | García Castaño, Almudena | - |
dc.contributor.author | Carral Maseda, Alberto | - |
dc.contributor.author | Iglesias Docampo, Lara | - |
dc.contributor.author | Pérez Segura, Pedro | - |
dc.contributor.author | Ceballos Lenza, Isaac | - |
dc.contributor.author | Gutiérrez Calderón, Vanesa | - |
dc.contributor.author | Fuster Salvà, José | - |
dc.contributor.author | Pena Álvarez, Carolina | - |
dc.contributor.author | Hernandez, Irene | - |
dc.contributor.author | Barco Morillo, Edel del | - |
dc.contributor.author | Chaves Conde, Manuel | - |
dc.contributor.author | Martínez Galán, Joaquina | - |
dc.contributor.author | Durán Sánchez, Marisa | - |
dc.contributor.author | Quiroga Garcia, Vanesa | - |
dc.contributor.author | Ortega, Eugenia | - |
dc.date.accessioned | 2024-03-14T11:29:32Z | - |
dc.date.available | 2024-03-14T11:29:32Z | - |
dc.date.issued | 2023-08-01 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/2445/208761 | - |
dc.description.abstract | Objectives: The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy. Materials and methods: This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high accumulated dose of PT, or PT refractoriness. Results: A total of 531 patients from 16 hospitals in Spain were enrolled. The median age was 66 years, 82.7% were male, and 83.5% were current/former smokers. Patients were ineligible to receive PT due to ECOG 2 (50.3%), comorbidities (32%), PT cumulative dose ≥ 225 mg/m2 (10.5%), or PT refractoriness (7.2%). Response rate was 37.7%. Median duration of response was 5.6 months (95% CI: 4.4-6.6). With a median follow-up of 8.7 months (95% CI: 7.7-10.2), median PFS and OS were 4.5 months (95% CI: 3.9-5.0) and 8.9 months (95% CI: 7.8-10.3), respectively. Patients treated with immunotherapy after ERBITAX had better OS with a median of 29.8 months compared to 13.8 months for those who received other treatments. The most common grade ≥ 3 toxicities were acne-like rash in 36 patients (6.8%) and oral mucositis in 8 patients (1.5%). Five (0.9%) patients experienced grade ≥ 3 febrile neutropenia. Conclusion: This study confirms the real-world efficacy and tolerability of ERBITAX as first-line treatment in recurrent/metastatic SCCHN when PT is not feasible. Immunotherapy after treatment with ERBITAX showed remarkable promising survival, despite potential selection bias. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2023.1226939 | - |
dc.relation.ispartof | Frontiers In Oncology, 2023, vol. 13 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2023.1226939 | - |
dc.rights | cc-by (c) Rubió-Casadevall, Jordi et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalts hospitalitzats | - |
dc.subject.classification | Càncer de cap | - |
dc.subject.classification | Càncer de coll | - |
dc.subject.classification | Anticossos monoclonals | - |
dc.subject.other | Hospital patients | - |
dc.subject.other | Head cancer | - |
dc.subject.other | Neck cancer | - |
dc.subject.other | Monoclonal antibodies | - |
dc.title | TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 739038 | - |
dc.date.updated | 2024-03-13T19:34:25Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
827631.pdf | 4.86 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License